TICKERNERD
Menu
AIMAIMHealthcare · Biotechnology

AIM Stock Forecast: AIM ImmunoTech, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$0.26
+3.36% on the day

The 2 Wall Street analysts covering AIM ImmunoTech, Inc. hold a median 12-month price target of $4.25 — +1544.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 20 of 100 as at 22 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$7.9M
Ticker Nerd rank
20 / 100
Median analyst target
$4.25
Analysts covering
2
Total return, dividends reinvested
1W
+17.5%
1M
+3.4%
YTD
−76.4%
1Y
−90.1%
From 52W high
−90.7%
From 52W low
+17.5%
$0.22
$2.79
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

AIM stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores AIM ImmunoTech, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
20 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
94
Revisions
68
Growth
55
Volatility
37
Accruals
26
Momentum
26
Value
12
Quality
6
Issuance
5

Size (94): Smaller than most of the companies we track.

Issuance (5): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

AIM stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on AIM, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00Oct 25Jan 26Apr 26Jul 26AIMHigh $7.00Median $4.25Low $1.50

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says2 analysts
2 Buy0 Hold0 Sell
Low $1.50Median $4.25High $7.00

The green dot is the last close — the median target sits +1544.7% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
20 Aug 2026Ascendiant CapitalMaintainsBuy—
1 June 2026Ascendiant CapitalMaintainsBuy—
10 Apr 2026Ascendiant CapitalMaintainsBuy—
8 Dec 2025Ascendiant CapitalMaintainsBuy—
3 Oct 2025Ascendiant CapitalMaintainsBuy—
10 Dec 2024Ascendiant CapitalMaintainsBuy—
22 Oct 2024Maxim GroupMaintainsBuy—
3 Sept 2024Ascendiant CapitalMaintainsBuy—
10 Oct 2019Maxim GroupUpgradeBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AIM appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

AIM analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

AIM ImmunoTech, Inc. (AIM) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.0×

Cheaper than 76% of US stocks

Price / sales
82.8×

Cheaper than 4% of US stocks

Price / book
1.0×

Cheaper than 75% of US stocks

EV / EBITDA
−0.2×

Cheaper than 62% of US stocks

Growth & margins
Revenue growth (YoY)
4.0%

Higher than 36% of US stocks

Earnings growth (YoY)
37.5%

Higher than 70% of US stocks

Gross margin
81.8%

Higher than 92% of US stocks

Operating margin
−13511.5%

Higher than 2% of US stocks

Net margin
−45.5%

Higher than 11% of US stocks

Returns & dividend
Return on equity
−2382.3%

Higher than 1% of US stocks

Return on assets
−82.6%

Higher than 4% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

AIM vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
AIMAIM ImmunoTech, Inc.$7.9M
20
APREAprea Therapeutics, Inc.$7.9M
44
ERNAErnexa Therapeutics, Inc.$7.9M
34
ACXPAcurx Pharmaceuticals, Inc.$7.7M
24
TRAWTraws Pharma, Inc.$8.0M
48
AZTRAzitra, Inc.$8.0M
28
XBIOXenetic Biosciences, Inc.$8.2M
39

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own AIM ImmunoTech, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest AIM news & analysis

AIM ImmunoTech CEO Highlights Biodefense and Military Force Protection in Newly Published ‘Breaking Defense' Article

GlobeNewsWire · 12 Aug 2026positive

AIM ImmunoTech CEO Thomas K. Equels authored an article in "Breaking Defense" calling for proactive evaluation of broad-spectrum antiviral countermeasures ahead of emerging viral threats, focusing on biodefense and military force protection. The piece highlights the potential role of such countermeasures in national defense planning.

Why it matters — AIM watchers would care because the CEO's publication in a defense-focused outlet raises the profile of the company's antiviral platform in the biodefense and military-protection space.

AIM ImmunoTech Ahead of Schedule on ‘Last Dose' DURIPANC Critical Clinical Inflection Point

GlobeNewsWire · 3 Aug 2026positive

AIM ImmunoTech announced it is ahead of schedule on the "last dose" critical clinical inflection point for its DURIPANC study of Ampligen. This milestone advances the drug toward a key clinical benefit readout planned for December 2026 and an overall survival analysis in mid-2027.

Why it matters — The accelerated progress brings AIM ImmunoTech closer to important clinical data readouts for Ampligen that could provide key insights into the drug's efficacy.

FAQ

Frequently asked questions about AIM stock

What is the AIM stock price forecast for 2026-2027?

The 2 Wall Street analysts covering AIM ImmunoTech, Inc. have a median 12-month price target of $4.25, with estimates ranging from $1.5 to $7. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is AIM stock a buy right now?

Of the 2 analysts covering AIM ImmunoTech, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks AIM ImmunoTech, Inc. 20 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank AIM?

As at 22 Aug 2026, AIM ImmunoTech, Inc. ranks 20 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (94 of 100).

Will AIM stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +1544.7% from the last close, and Ticker Nerd's factor model ranks AIM ImmunoTech, Inc. 20 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the AIM stock forecast for 2030?

No analyst covering AIM ImmunoTech, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AIM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1.5 to $7 over the next 12 months.

How has AIM stock performed over the past year?

AIM ImmunoTech, Inc. returned -90.1% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does AIM ImmunoTech, Inc. do?

AIM ImmunoTech Inc. is a biopharmaceutical company specializing in immunology-focused drug development.

What is the latest news on AIM?

The most recent item we track (GlobeNewsWire, 12 Aug 2026): "AIM ImmunoTech CEO Highlights Biodefense and Military Force Protection in Newly Published ‘Breaking Defense' Article". AIM ImmunoTech CEO Thomas K. Equels authored an article in "Breaking Defense" calling for proactive evaluation of broad-spectrum antiviral countermeasures ahead of emerging viral threats, focusing on biodefense and military force protection. The piece highlights the potential role of such countermeasures in national defense planning.

Company

About AIM ImmunoTech, Inc.

AIM ImmunoTech Inc. is a biopharmaceutical company specializing in immunology-focused drug development. The company concentrates on researching and developing therapeutics for multiple types of cancers, viral diseases, immune disorders, and immune-deficiency conditions, addressing areas where existing treatment options are limited or inadequate. AIM ImmunoTech’s work centers on modulating the immune system, with a particular emphasis on leveraging innate immune pathways. Its lead product, Ampligen (rintatolimod), is a double-stranded RNA immunomodulator being developed for use in oncology, viral infections, and immune-related disorders. Another key product, Alferon N Injection (interferon alfa), is a purified, natural-source alpha interferon indicated for certain viral conditions. AIM ImmunoTech operates primarily in the healthcare and biotechnology sector in the United States and collaborates with clinical and academic partners to advance its programs. Founded in 1966 and headquartered in Ocala, Florida, the company plays a niche role in the immuno-pharma segment by focusing on immune-based therapeutic approaches.

CEO Mr. Thomas K. Equels Esq., J.D., M.S. · 19 employees · United States · https://aimimmuno.com